LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)
NCT07408531
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (based on the guidelines of the Potter and American Cancer Society (ACS)) can help identify individuals at risk who are not currently included in the U.S. Preventive Services Task Force (USPSTF) guidelines.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Lung Cancer Screening
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of Illinois at Chicago
- Last updated on ClinicalTrials.gov
- August 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Illinois · 2
- UI Health · Chicago, IL
- UI Health 55th and Pulaski Health Collaborative · Chicago, IL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.